[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:diffuse-large-b-cell-lymphoma:x-linked-lymphoproliferative-syndrome-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Diffuse Large B-Cell Lymphoma","X-linked Lymphoproliferative Syndrome 1",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06789159","A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)",[12],"Phase 1","RECRUITING","2026-08-26T02:17:18.747857Z","2026-05-05T02:43:28.339016Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[20],"Phase 2","2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[20],"NOT_YET_RECRUITING","2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z"]